Progyny, Inc. (NASDAQ:PGNY) Given Consensus Recommendation of “Hold” by Analysts

Shares of Progyny, Inc. (NASDAQ:PGNY) have been given an average rating of “Hold” by the thirteen analysts that are covering the company, MarketBeat reports. Nine research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $25.00.

PGNY has been the topic of a number of research analyst reports. JMP Securities cut Progyny from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 19th. Barclays reduced their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Bank of America decreased their price objective on Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Progyny in a research note on Tuesday, October 1st. Finally, Truist Financial reiterated a “hold” rating and set a $19.00 price target (down from $26.00) on shares of Progyny in a research report on Wednesday, November 13th.

Institutional Trading of Progyny

Several large investors have recently modified their holdings of PGNY. Cetera Advisors LLC purchased a new stake in Progyny in the 1st quarter worth approximately $321,000. SG Americas Securities LLC purchased a new stake in Progyny in the second quarter worth $374,000. Cooper Financial Group purchased a new stake in Progyny in the second quarter worth $314,000. M&G Plc boosted its holdings in Progyny by 20.5% in the second quarter. M&G Plc now owns 36,641 shares of the company’s stock valued at $1,063,000 after acquiring an additional 6,223 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its position in Progyny by 141.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 20,393 shares of the company’s stock valued at $583,000 after purchasing an additional 11,934 shares during the period. 94.93% of the stock is owned by institutional investors.

Progyny Trading Down 1.7 %

Shares of PGNY opened at $14.61 on Tuesday. Progyny has a 12-month low of $13.39 and a 12-month high of $42.08. The company has a market cap of $1.24 billion, a PE ratio of 25.19, a price-to-earnings-growth ratio of 1.73 and a beta of 1.35. The stock has a 50-day moving average price of $15.53 and a 200-day moving average price of $21.34.

Progyny (NASDAQ:PGNY) last announced its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.26). The company had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.16 earnings per share. As a group, analysts predict that Progyny will post 0.59 earnings per share for the current year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.